The potential nephroprotective effects of GLP-1RAs had been reported in a further analysis of renal outcomes in a series of CVOTs trials that showed reduction in proteinuria and hinted at slowing eGFR decline
Skipping meals can cost you, especially if it means skimping on protein
Clinical trials have focused on people living with obesity, early research shows it could, if licensed, be used for conditions like type 2 diabetes and fatty liver disease
If you take more than what you need, your body passes the rest out through your pee
GIP Receptor : Activating the GIP receptor further enhances insulin release and may have additional effects on fat metabolism
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a promising therapeutic option for promoting WL beyond lifestyle modifications, demonstrating efficacy in non-surgical populations [9, 10]